Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Farley
NRG Oncology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
145 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tohoku University School of Medicine
Sendai, Aoba-ku, Japan
- Kure National Hospital
Kure, Hiroshima, Japan
- Hokkaido University Hospital
Sapporo, Hokkaido, Japan
- Hyogo Cancer Center
Akashi, Hyōgo, Japan
- Iwate Medical University School of Medicine
Morioka, Iwate, Japan
- Kagoshima City Hospital
Kagoshima, Kagoshima-ken, Japan
- Niigata University Medical and Dental Hospital
Niigata, Niigata, Japan
- University of the Ryukyus Hospital-Col Health Scnc
Nakagami-gun, Okinawa, Japan
- Shizuoka Cancer Center
Shizuoka, Suntou, Japan
- Keio University
Shinjuku-ku, Tokyo, Japan
- Shikoku Cancer Center
Matsuyama, Japan
- National Kyushu Cancer Center
Minamiku, Japan
- Jikei University School of Medicine
Minato-ku, Tokyo, Japan
- Kinki University
Osaka, Osaka, Japan
- Saitama Medical University International Medical Center
Saitama, Japan
- National Cancer Center Hospital
Tokyo, Japan
- Tottori University
Tottori, Japan
- Keimyung University-Dongsan Medical Center
Jung-Ku, Daegu, South Korea
- National Cancer Center-Korea
Goyang-si, Gyeonggi-do, South Korea
- Samsung Medical Center
Seoul, Korea, South Korea
- Asan Medical Center
Seoul, South Korea
- Gangnam Severance Hospital
Seoul, South Korea
- Korea Cancer Center Hospital
Seoul, South Korea
- Seoul National University Hospital
Seoul, South Korea
- Saint Joseph'S Hospital and Medical Center
Phoenix, Arizona, United States
- Providence Saint Joseph Medical Center/disney Family Cancer Center
Burbank, California, United States
- Los Angeles County-Usc Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California, United States
- University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, United States
- Hartford Hospital
Hartford, Connecticut, United States
- Saint Francis Hospital and Medical Center
Hartford, Connecticut, United States
- the Hospital of Central Connecticut
New Britain, Connecticut, United States
- Florida Hospital Orlando
Orlando, Florida, United States
- Memorial University Medical Center
Savannah, Georgia, United States
- Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
- Northwestern University
Chicago, Illinois, United States
- Rush University Medical Center
Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Sudarshan K Sharma Md Limted-Gynecologic Oncology
Hinsdale, Illinois, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2010
- Primary completion
- 31 Jan 2015
- Completion
- 31 Jan 2015
- Last update posted
- 8 Aug 2019
- Registered enrollment
- 90
- Registry id
- NCT01196429
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.